Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
This review describes the mouse knockout models of cholesterol synthesis, together with human malformations and drugs that target cholesterogenic enzymes. Generally, the sooner a gene acts in cholesterol synthesis, the earlier the phenotype occurs. Humans with loss of function of early cholesterogenic enzymes have not yet been described, and in the mouse, loss of Hmgcr is preimplantation lethal. Together, these results indicate that the widely prescribed cholesterol-lowering statins are potentially teratogenic. The Mvk knockout is early embryonic lethal in the mouse, the absence of Fdft1 is lethal at E9.5-12.5 dpc, while the Cyp51 knockouts die at 15.0 dpc. Fungal CYP51 inhibitor azoles are teratogenic in humans, potentially leading to symptoms of Antley-Bixler syndrome. The X-linked mutations in Nsdhl and Ebp are embryonic lethal in male mice, while heterozygous females are also affected. Consequently, the anticancer drugs, tamoxifen and toremifene, inhibiting human EBP, may be harmful in early pregnancy. The Dhcr7 and Dhcr24 knockout mice die shortly after birth, while humans survive with Smith-Lemli-Opitz syndrome or desmosterolosis. Since cholesterol is essential for hedgehog signaling, disturbance of this pathway by antipsychotics and -depressants explains some drug side effects. In conclusion, defects in cholesterol synthesis are generally lethal in mice, while humans with impaired later steps of the pathway can survive with severe malformations. Evidence shows that drugs targeting or, by coincidence, inhibiting human cholesterol synthesis are better avoided in early pregnancy. Since some drugs with teratogenic potential still stay on the market, this should be avoided in new cholesterol-related drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hedgehog: functions and mechanisms
Varjosalo, M., & Taipale, J. (2008) · Genes & Development · doi:10.1101/gad.1693608 · Cited by 1,217 · cited 1×
“The possibility that differentially processed hedgehog proteins may have altered signaling efficiency is discussed in several reviews (Waterham, 2006; Simpson et al., 2009; Varjosalo and Taipale, 2008).”
BackgroundNapoli, C., D'Armiento, F. P., Mancini, F. P., Postiglione, A., Witztum, J. L., Palumbo, G., & Palinski, W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119813 · Cited by 1,014 · cited 1×
“Fatty streak occurrence in the fetal aorta is dependent upon maternal cholesterol levels (Napoli et al., 1997, 1999).”
BackgroundA newly recognized syndromeof multiple congenital anomalies
Smith, D. W., Lemli, L., & Opitz, J. M. (1964) · The Journal of Pediatrics · doi:10.1016/s0022-3476(64)80264-x · Cited by 650
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620 · cited 1×
“MVK is a part of the multistep pathway that leads to synthesis of nonsterol isoprenoids, such as farnesyl, dolichol, heme-A, ubiquinone (coenzyme Q), and isoprene itself (Buhaescu and Izzedine, 2007).”
BackgroundMutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K., & Miller, W. L. (2004) · Nature Genetics · doi:10.1038/ng1300 · Cited by 509 · cited 1×
“It was later revealed that the cause of the abnormal sterol profile and genital malformations lies in mutations of the POR gene (Fluck et al., 2004).”
BackgroundMolecular basis of resistance to azole antifungals.
Lupetti, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02280-3 · Cited by 449
Mutations in the Human Sterol Δ7-Reductase Gene at 11q12-13 Cause Smith-Lemli-Opitz Syndrome
Wassif, C. A., Maslen, C., Kachilele-Linjewile, S., Lin, D., Linck, L. M., Connor, W. E., Steiner, R. D., & Porter, F. D. (1998) · The American Journal of Human Genetics · doi:10.1086/301936 · Cited by 418 · cited 2×
“…defects in sterol biosynthesis, such as Smith-Lemli-Opitz (SLOS) syndrome caused by mutations in the 7-dehydrocholesterol reductase DHCR7 gene (Wassif et al., 1998) However, in addition to genetic defects, impairment of sterol biosynthesis by drug interventions can also be causative, such as…”
BackgroundResultA defective response to Hedgehog signaling in disorders of cholesterol biosynthesis
Cooper, M. K., Wassif, C. A., Krakowiak, P. A., Taipale, J., Gong, R., Kelley, R. I., Porter, F. D., & Beachy, P. A. (2003) · Nature Genetics · doi:10.1038/ng1134 · Cited by 390
Mutations in the Δ7-sterol reductase gene in patients with the Smith–Lemli–Opitz syndrome
Fitzky, B. U., Witsch-Baumgartner, M., Erdel, M., Lee, J. N., Paik, Y.-K., Glossmann, H., Utermann, G., & Moebius, F. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8181 · Cited by 384
Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome
Irons, M., Roy Elias, E., Salen, G., Tint, G. S., & Batta, A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90983-n · Cited by 368
Fluconazole-induced congenital anomalies in three infants
Pursley, T. J., Blomquist, I. K., Abraham, J., Andersen, H. F., & Bartley, J. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.336 · Cited by 246 · cited 2×
“…the 7-dehydrocholesterol reductase DHCR7 gene (Wassif et al., 1998) However, in addition to genetic defects, impairment of sterol biosynthesis by drug interventions can also be causative, such as in children born to mothers treated with fluconazole (Aleck and Bartley, 1997; Pursley et al., 1996).”
BackgroundShen, A. L., O'Leary, K. A., & Kasper, C. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111408200 · Cited by 225 · cited 3×
“The first report of the Por knockout (Shen et al., 2002) shows a variety of embryonic defects from day 10.5 of gestation.”
BackgroundInfluentialOtto, D. M. E., Henderson, C. J., Carrie, D., Davey, M., Gundersen, T. E., Blomhoff, R., Adams, R. H., Tickle, C., & Wolf, C. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6103-6116.2003 · Cited by 189 · cited 2×
“A second—independent—knockout of the Por gene (Otto et al., 2003) also reported lethality at a similar stage of development as the aforementioned model (E9.”
BackgroundResultWassif, C. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.555 · Cited by 164
Fukami, M., Horikawa, R., Nagai, T., Tanaka, T., Naiki, Y., Sato, N., Okuyama, T., Nakai, H., Soneda, S., Tachibana, K., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0810 · Cited by 155 · cited 3×
“Mutations in the POR gene explained not only some phenotypes of ABS, but also the combined partial impairment of the steroidogenic enzymes, 17-hydroxylase and 21-hydroxylase, where affected patients show evidence of impaired steroid synthesis (Fukami et al., 2005, 2006).”
BackgroundPrenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes
Taguchi, N., Rubin, E. T., Hosokawa, A., Choi, J., Ying, A. Y., Moretti, M. E., Koren, G., & Ito, S. (2008) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.06.009 · Cited by 142 · cited 4×
“The study concluded that the absolute risk of teratogenicity of statins appears relatively small, but a larger scale study is needed to further characterize the teratogenic potential (Taguchi et al., 2008).”
BackgroundMethodInfluentialEffects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132 · cited 1×
“Under chemotherapy, up to 85% of patients can develop liver steatosis (Ramadori and Cameron, 2010).”
BackgroundGylling, H., Pyrhönen, S., Mäntylä, E., Mäenpää, H., Kangas, L., & Miettinen, T. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2900 · Cited by 112
Defects of cholesterol biosynthesis
Waterham, H. R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.027 · Cited by 108 · cited 3×
“5 dpc, it represented only 30% (Waterham, 2006).”
BackgroundDebeljak, N., Fink, M., & Rozman, D. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00418-6 · Cited by 103 · cited 3×
“It is important to note that the fungal CYP51 enzymes share approximately 30–40% identity to mammalian CYP51s (Debeljak et al., 2003).”
BackgroundSelf-citationAbnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia
Kelley, R. I., Kratz, L. E., Glaser, R. L., Netzloff, M. L., Miller Wolf, L., & Jabs, E. W. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10510 · Cited by 95 · cited 2×
“Although a modified sterol profile in the fluconazole-exposed patient suggested a deficiency of lanosterol CYP51A1, mutational analysis of the CYP51A1 gene showed no obvious pathogenic mutations in exons or exon-intron boundaries (Kelley et al., 2002).”
Background3β-Hydroxysterol Δ7-reductase and the Smith–Lemli–Opitz syndrome
Correa-Cerro, L. S., & Porter, F. D. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.09.017 · Cited by 92 · cited 1×
“It was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis (Correa-Cerro and Porter, 2005).”
BackgroundPharmacological Analysis of Sterol Δ8-Δ7 Isomerase Proteins with [3H]Ifenprodil
Moebius, F. F., Reiter, R. J., Bermoser, K., Glossmann, H., Cho, S. Y., & Paik, Y.-K. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.3.591 · Cited by 81 · cited 3×
“The positive side effects of tamoxifen and toremifene due to inhibition of EBP A variety of experimental drugs with nanomolar affinity for human EBP (e.g., MDL28815, AY9944, triparanol, and U18666A) were identified in the late 1990s (Moebius et al., 1998).”
BackgroundFukami, M., Hasegawa, T., Horikawa, R., Ohashi, T., Nishimura, G., Homma, K., & Ogata, T. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000195825.31504.28 · Cited by 79 · cited 1×
“Mutations in the POR gene explained not only some phenotypes of ABS, but also the combined partial impairment of the steroidogenic enzymes, 17-hydroxylase and 21-hydroxylase, where affected patients show evidence of impaired steroid synthesis (Fukami et al., 2005, 2006).”
BackgroundKoide, T., Hayata, T., & Cho, K. W. Y. (2006) · Development · doi:10.1242/dev.02393 · Cited by 69 · cited 1×
“Since many SLOS developmental malformations occur in tissues and organs where hedgehog signaling is required for development, deregulation of the signaling is believed to contribute to the SLOS phenotype (Koide et al., 2006).”
Background
Cited by
Lorbek, G., Lewinska, M., & Rozman, D. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08432.x · Cited by 196
Self-citationKeber, R., Motaln, H., Wagner, K. D., Debeljak, N., Rassoulzadegan, M., Ačimovič, J., Rozman, D., & Horvat, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.253245 · Cited by 102
Self-citationIntracellular Cholesterol Synthesis and Transport
Shi, Q., Chen, J., Zou, X., & Tang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.819281 · Cited by 73
“, 2013), and DHCR24 heterozygous knockout in mice reduces cholesterol levels without causing health problems (Horvat et al., 2011).”
BackgroundKorade, Z., Kim, H.-Y. H., Tallman, K. A., Liu, W., Koczok, K., Balogh, I., Xu, L., Mirnics, K., & Porter, N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01696 · Cited by 65
Metadata
- Authors
- Horvat, S., Mcwhir, J., & Rozman, D.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2011-01-20
- Volume
- 43
- Issue
- 1
- Pages
- 69-90
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W1968459053
- Cited by
- 67
- References
- 25
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.